Revenue from Contracts with Customers (Tables)

6 Months Ended

Jun. 30, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table summarizes revenue by revenue source as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
Major Products/Service Lines (in thousands)	2023		2022		2023		2022
Product revenue, net(1)	$	314,084	$	217,782	$	606,340	$	397,791
License and royalty revenues(2)	7,616		5,941		16,144		34,812
Total revenues	$	321,700	$	223,723	$	622,484	$	432,603

________________________________

(1)The Company’s product revenue includes PYLARIFY and DEFINITY among other products. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all its principal products.

(2)The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG.

Revenue by product category on a net basis is as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2023		2022		2023		2022
PYLARIFY	$	210,522	$	130,232	$	405,992	$	223,009
Other radiopharmaceutical oncology	818		928		1,535		2,255
Total radiopharmaceutical oncology	211,340		131,160		407,527		225,264
DEFINITY	70,529		62,306		139,353		120,634
TechneLite	21,594		19,440		42,580		42,045
Other precision diagnostics	5,454		5,363		11,261		10,628
Total precision diagnostics	97,577		87,109		193,194		173,307
Strategic partnerships and other revenue	12,783		5,454		21,763		34,032
Total revenues	$	321,700	$	223,723	$	622,484	$	432,603